{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:06:00Z","timestamp":1789049160397,"version":"build-2803163510"},"reference-count":45,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Psoriasis is a chronic immune-mediated inflammatory skin disease often associated with systemic inflammation and multiple comorbidities, resulting in a substantial negative impact on patients\u2019 quality of life and mental health. In addition to cutaneous and joint involvement, patients frequently experience psychological distress, social stigma, and symptoms of anxiety and depression, which may be comparable in clinical relevance to the physical manifestations of the disease. In recent years, biologic therapies have become increasingly established in the treatment of psoriasis due to their targeted action on key inflammatory pathways involved in disease pathogenesis and their high clinical efficacy. Beyond improving disease severity, biologic agents have also been associated with meaningful improvements in health-related quality of life and mental health outcomes. Importantly, currently available evidence suggests that psychological and quality-of-life outcomes in psoriasis are influenced by multiple interacting clinical and psychosocial factors. This narrative review summarizes recent scientific evidence on the relationship between psoriasis, quality of life, and mental health, with particular emphasis on the impact of biologic therapy on these outcomes. The available data suggest that treatment response reflects a multidimensional process, in which clinical improvement, psychological status, and broader psychosocial factors interact to influence patient-reported outcomes. Overall, the reviewed studies indicate that biologic therapies not only reduce disease severity but are also associated with meaningful improvements in health-related quality of life and psychological well-being in patients with psoriasis.<\/jats:p>","DOI":"10.3390\/jcm15114353","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:11:04Z","timestamp":1780593064000},"page":"4353","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Impact of Biologic Therapy on Quality of Life and Mental Health in Patients with Psoriasis"],"prefix":"10.3390","volume":"15","author":[{"given":"Gabriel\u0117","family":"\u017daliukait\u0117","sequence":"first","affiliation":[{"name":"Clinic of Infectious Diseases and Dermatovenereology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, M. K. \u010ciurlionio g. 21, 03101 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8852-1846","authenticated-orcid":false,"given":"Tadas","family":"Raudonis","sequence":"additional","affiliation":[{"name":"Clinic of Infectious Diseases and Dermatovenereology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, M. K. \u010ciurlionio g. 21, 03101 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/JD9.0000000000000343","article-title":"Effects of Biologics on Mental Health and Health-Related Quality of Life in Patients With Psoriasis: A Repeated Cross-Sectional Survey in Chinese Population","volume":"6","author":"Liu","year":"2023","journal-title":"Int. J. Dermatol. Venereol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Timis, T.L., Beni, L., Mocan, T., Florian, I.A., and Orasan, R.I. (2023). Biologic therapies decrease disease severity and improve depression and anxiety symptoms in psoriasis patients. Life, 13.","DOI":"10.3390\/life13051219"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2247106","DOI":"10.1080\/09546634.2023.2247106","article-title":"The economic burden and quality of life of patients with psoriasis treated with biologics in China","volume":"34","author":"Min","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.5937\/afmnai41-42126","article-title":"The impact of biological therapy on health-related quality of life in patients with psoriasis","volume":"40","year":"2023","journal-title":"AFMN Biomed."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4103\/ijd.ijd_241_22","article-title":"The effects of methotrexate and biologics on the symptoms of depression and anxiety in patients with psoriasis","volume":"68","author":"Altunay","year":"2023","journal-title":"Indian J. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.35988\/sm-hs.2024.115","article-title":"Omega\u20133 riebal\u0173 r\u016bg\u0161tys ir l\u0117tin\u0117s u\u017edegimin\u0117s odos ligos","volume":"34","year":"2024","journal-title":"Sveik. Moksl."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Wu, C.L., Chang, Y.C., Yao, W.T., and Chiang, T.I. (2024). Exploring the Effectiveness of Biological Therapy in Patients with Psoriasis: Body Image and Quality of Life. Medicina, 60.","DOI":"10.3390\/medicina60010160"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kamata, M., and Tada, Y. (2020). Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: A literature review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051690"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2147\/PTT.S356568","article-title":"Biologics can significantly improve Dermatology Life Quality Index (DLQI) in psoriatic patients: A systematic review","volume":"12","author":"Rustemeyer","year":"2022","journal-title":"Psoriasis Targets Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.35988\/sm-hs.2023.103","article-title":"Psoriazinis artritas: Epidemiologija, etiologija, diagnostika ir gydymas","volume":"33","year":"2023","journal-title":"Sveik. Moksl."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Balato, A., Zink, A., Babino, G., Buononato, D., Kiani, C., Eyerich, K., Ziehfreund, S., and Scala, E. (2022). The impact of psoriasis and atopic dermatitis on quality of life: A literature research on biomarkers. Life, 12.","DOI":"10.3390\/life12122026"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s13555-022-00695-0","article-title":"Impact of psoriatic disease on quality of life: Interim results of a global survey","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/09546634.2018.1476654","article-title":"Comparison of mental health outcomes among adults with psoriasis on biologic versus oral therapies: A population-based study","volume":"30","author":"Salame","year":"2019","journal-title":"J. Dermatol. Treat."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lee, S.W., Lee, Y., Kang, C., Cho, H., Park, J.H., Dong, J.J., Wolde, H.M., Shin, W.S., Jung, H., and Bae, Y. (2026). Risk of anxiety disorder following ankylosing spondylitis, 2012-2023: A nationwide cohort study in South Korea. Front. Psychiatry, 17.","DOI":"10.3389\/fpsyt.2026.1686890"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/PTT.S519420","article-title":"Challenges psoriasis and its impact on quality of life: Challenges in treatment and management","volume":"15","author":"Ponikowska","year":"2025","journal-title":"Psoriasis Targets Ther."},{"key":"ref_16","unstructured":"Petra\u0161kien\u0117, R. (2016). \u017dvyneline Sergan\u010di\u0173 Pacient\u0173 su Sveikata Susijusios Gyvenimo Kokyb\u0117s Vertinimas. [Ph.D. Thesis, Lietuvos Sveikatos Moksl\u0173 Universitetas, Medicinos Akademija]."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Cipolla, S., Catapano, P., Bonamico, A.F., De Santis, V., Murolo, R., Romano, F., Volpicelli, A., Perris, F., Schiavo, A.L., and Fabrazzo, M. (2024). Factors associated with anxiety, depression, and quality of life in patients with psoriasis: A Cross-Sectional Study. Brain Sci., 14.","DOI":"10.3390\/brainsci14090865"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"115078","DOI":"10.1016\/j.psychres.2023.115078","article-title":"Epidemiology of mental health comorbidity in patients with psoriasis: An analysis of trends from 1986 to 2019","volume":"321","author":"Liu","year":"2023","journal-title":"Psychiatry Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"110347","DOI":"10.1016\/j.jpsychores.2020.110347","article-title":"Suicidal risks with psoriasis and atopic dermatitis: Systematic review and meta-analysis","volume":"141","author":"Pompili","year":"2021","journal-title":"J. Psychosom. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Tokuyama, M., and Mabuchi, T. (2020). New Treatment Addressing the Pathogenesis of Psoriasis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207488"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2147\/PTT.S535900","article-title":"The Skin-Brain Axis in Psoriasis and Depression: Roles of Inflammation, Hormones, Neuroendocrine Pathways, Neuropeptides, and the Microbiome","volume":"15","author":"Tang","year":"2025","journal-title":"Psoriasis"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1080\/09546634.2022.2081655","article-title":"Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: Results from an Italian 28-week retrospective study","volume":"33","author":"Megna","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e15214","DOI":"10.1111\/dth.15214","article-title":"Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study","volume":"35","author":"Ruggiero","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"260","DOI":"10.71152\/ajms.v15i5.555","article-title":"Psychological impact on the quality-of-life in patients of psoriasis vulgaris: A systemic review","volume":"15","author":"Ghosh","year":"2024","journal-title":"Asian J. Med. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaad.2017.05.019","article-title":"Psoriasis and suicidality: A systematic review and meta-analysis","volume":"77","author":"Singh","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/ced.14218","article-title":"Sex- and gender-associated clinical and psychosocial characteristics of patients with psoriasis","volume":"45","author":"Napolitano","year":"2020","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e010","DOI":"10.1097\/JW9.0000000000000010","article-title":"The impact of gender and sex in psoriasis: What to be aware of when treating women with psoriasis","volume":"8","author":"Guillet","year":"2022","journal-title":"Int. J. Women\u2019s Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1684\/ejd.2020.3768","article-title":"Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: Results from a large-scale survey in routine care","volume":"30","author":"Augustin","year":"2020","journal-title":"Eur. J. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5200\/sm-hs.2018.013","article-title":"Ret\u0173 odos lig\u0173 poveikis pacient\u0173 gyvenimo kokybei ir psichinei sveikatai","volume":"28","year":"2018","journal-title":"Sveik. Moksl."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.19039","article-title":"British association of dermatologists guidelines for biologic therapy for psoriasis 2020: A rapid update","volume":"183","author":"Smith","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","article-title":"Biologic and small-molecule therapies for moderate-to-severe psoriasis: Focus on psoriasis comorbidities","volume":"37","author":"Jiang","year":"2023","journal-title":"BioDrugs"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2147\/PTT.S526748","article-title":"Patient-reported well-being in value-based routine care using tildrakizumab: 52-week interim data of the phase IV positive study","volume":"15","author":"Mrowietz","year":"2025","journal-title":"Psoriasis Targets Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2200872","DOI":"10.1080\/09546634.2023.2200872","article-title":"Quality of life and patient-reported symptoms in a phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: Week 28 interim analysis","volume":"34","author":"Bhatia","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Licata, G., Di Brizzi, E.V., Castelli, F., Giuffrida, G., Stroppiana, E., Dattola, A., Richetta, A.G., De Col, E., Peila, R., and Siliquini, N. (2025). Tildrakizumab and Quality of Life: Deep Dive into the Impact of Psoriasis and Treatment on Different Domains\u2014Should Psychosocial Life Impairment Be Considered a Comorbidity?. J. Clin. Med., 14.","DOI":"10.3390\/jcm14010223"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s13555-025-01389-z","article-title":"Efficacy and Safety of Apremilast Over 52 Weeks in Patients with Plaque Psoriasis in High-Impact Areas and Impaired Quality of Life","volume":"15","author":"Augustin","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Cuniberti, F., Miniotti, M., Bailon, M., Mastorino, L., Ortoncelli, M., Picardi, A., Ribero, S., and Leombruni, P. (2026). From Skin Clearance to Psychological Wellbeing: Real-World Outcomes of Biologic Therapy in Psoriasis. Front. Psychol., 17.","DOI":"10.3389\/fpsyg.2026.1735777"},{"key":"ref_38","first-page":"1159","article-title":"Switching and multiple switching in psoriasis biologic therapy: Current evidence and future perspectives","volume":"25","author":"Megna","year":"2024","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaad.2024.02.039","article-title":"Mental Health Outcomes in Patients with Moderate to Severe Psoriasis Treated with Bimekizumab: Analysis of Phase 2\/3 Randomized Trials","volume":"91","author":"Blauvelt","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S758","DOI":"10.1192\/j.eurpsy.2022.1957","article-title":"Protocol for the Safety of Brodalumab Regarding Psychiatric Comorbidities in Patients with Psoriasis","volume":"65","author":"Pikou","year":"2022","journal-title":"Eur. Psychiatry"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1007\/s13555-025-01497-w","article-title":"Brodalumab: Seven-Year US Pharmacovigilance Report","volume":"15","author":"Lebwohl","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_42","first-page":"452","article-title":"Efficacy, Tolerability and Patient\u2019s Satisfaction for the Treatment of Moderate to Severe Plaque Psoriasis with Apremilast in the Real-Life Setting of Campania Region, Italy","volume":"158","author":"Licata","year":"2023","journal-title":"Ital. J. Dermatol. Venerol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s13555-021-00649-y","article-title":"Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial","volume":"12","author":"Strober","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.3899\/jrheum.121200","article-title":"Patient-Reported Health-Related Quality of Life with Apremilast for Psoriatic Arthritis: A Phase II, Randomized, Controlled Study","volume":"40","author":"Strand","year":"2013","journal-title":"J. Rheumatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/ajd.13864","article-title":"Mental Health, Insomnia and Suicidal Ideation During Treatment with Apremilast","volume":"63","author":"Cowan","year":"2022","journal-title":"Australas. J. Dermatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/11\/4353\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:28:14Z","timestamp":1780594094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/11\/4353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jcm15114353"],"URL":"https:\/\/doi.org\/10.3390\/jcm15114353","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]}}}